Regeneron Pharmaceuticals' Non Operating Income rose 91481.48% to $176.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 10482.92%. This contributed to the annual value of $1.7 billion for FY2025, which is 10092.37% up from last year.
According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Non Operating Income is $176.0 million, which was up 91481.48% from $755.8 million recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Non Operating Income ranged from a high of $755.8 million in Q3 2025 and a low of -$197.4 million during Q1 2022
For the 5-year period, Regeneron Pharmaceuticals' Non Operating Income averaged around $167.4 million, with its median value being $165.4 million (2021).
In the last 5 years, Regeneron Pharmaceuticals' Non Operating Income plummeted by 26878.45% in 2021 and then soared by 175965.91% in 2024.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Non Operating Income stood at -$122.2 million in 2021, then skyrocketed by 294.19% to $237.3 million in 2022, then dropped by 18.67% to $193.0 million in 2023, then tumbled by 111.19% to -$21.6 million in 2024, then soared by 914.81% to $176.0 million in 2025.
Its last three reported values are $176.0 million in Q4 2025, $755.8 million for Q3 2025, and $442.8 million during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value